A detailed history of Zurcher Kantonalbank (Zurich Cantonalbank) transactions in Recursion Pharmaceuticals, Inc. stock. As of the latest transaction made, Zurcher Kantonalbank (Zurich Cantonalbank) holds 52,530 shares of RXRX stock, worth $380,317. This represents 0.0% of its overall portfolio holdings.

Number of Shares
52,530
Previous 52,530 -0.0%
Holding current value
$380,317
Previous $346,000 -0.0%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 07, 2024

BUY
$5.92 - $8.6 $15,788 - $22,936
2,667 Added 5.35%
52,530 $346,000
Q2 2024

Jul 29, 2024

BUY
$7.35 - $10.05 $103,341 - $141,303
14,060 Added 39.27%
49,863 $373,000
Q1 2024

Apr 25, 2024

SELL
$9.13 - $15.52 $44,326 - $75,349
-4,855 Reduced 11.94%
35,803 $356,000
Q4 2023

Jan 30, 2024

BUY
$5.09 - $10.79 $51,067 - $108,256
10,033 Added 32.76%
40,658 $400,000
Q3 2023

Oct 25, 2023

SELL
$6.59 - $15.86 $3,347 - $8,056
-508 Reduced 1.63%
30,625 $234,000
Q2 2023

Aug 07, 2023

BUY
$4.56 - $9.94 $55,536 - $121,059
12,179 Added 64.26%
31,133 $232,000
Q4 2022

Feb 01, 2023

BUY
$7.16 - $12.7 $28,618 - $50,761
3,997 Added 26.72%
18,954 $146,000
Q3 2022

Nov 09, 2022

SELL
$7.83 - $13.6 $1,464 - $2,543
-187 Reduced 1.23%
14,957 $159,000
Q2 2022

Aug 09, 2022

BUY
$5.04 - $9.26 $76,325 - $140,233
15,144 New
15,144 $123,000
Q1 2022

Apr 21, 2022

SELL
$6.16 - $18.03 $98,960 - $289,651
-16,065 Closed
0 $0
Q4 2021

Feb 01, 2022

BUY
$16.14 - $21.86 $132,977 - $180,104
8,239 Added 105.28%
16,065 $275,000
Q3 2021

Nov 15, 2021

BUY
$19.03 - $41.33 $148,928 - $323,448
7,826 New
7,826 $180,000

Others Institutions Holding RXRX

About RECURSION PHARMACEUTICALS, INC.


  • Ticker RXRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 180,480,000
  • Market Cap $1.31B
  • Description
  • Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase IIa clinical trial to treat cerebral cav...
More about RXRX
Track This Portfolio

Track Zurcher Kantonalbank (Zurich Cantonalbank) Portfolio

Follow Zurcher Kantonalbank (Zurich Cantonalbank) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Zurcher Kantonalbank (Zurich Cantonalbank), based on Form 13F filings with the SEC.

News

Stay updated on Zurcher Kantonalbank (Zurich Cantonalbank) with notifications on news.